Arikci D

Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland.

6 papers · ORCID

ArticlePsilocybin

Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participants.

Arikci D, Borgulya J, Straumann I +8

Europe PMC2026
ArticlePsilocybin

The 3D-ASCr scale: A revalidation of the core dimensions of the Altered States of Consciousness Rating Scale 5D(11)-ASC for psychedelic research.

Stocker K, Hartmann M, Schmid Y +10

Europe PMC2026
ArticleLSD

Absolute Oral Bioavailability and Bioequivalence of LSD Base and Tartrate in a Double-Blind, Placebo-Controlled, Crossover Study.

Arikci D, Holze F, Mueller L +5

Europe PMC2025
ArticlePsilocybin

Motivation and retrospective appraisal of psychedelic study participation: a qualitative study in healthy volunteers.

Ley L, Liechti ME, Becker AM +6

Europe PMC2025
ArticleLSD

Pharmacological and non-pharmacological predictors of the LSD experience in healthy participants.

Vizeli P, Studerus E, Holze F +8

Europe PMC2024
ArticlePsilocybin

Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants.

Ley L, Holze F, Arikci D +11

Europe PMC2023